Myovant Sciences Ltd. Banner Image

Myovant Sciences Ltd.

  • Ticker MYOV
    Exchange NYSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Myovant Sciences Ltd. Logo Image
  • 201-500 Employees
  • Based in Brisbane, California
Myovant Sciences aspires to be the leading healthcare company focused on redefining care for women and for men. The company’s lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. The company has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1More receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG, a subsidiary of Takeda Pharmaceutical Company Limited, the originator of relugolix, previously granted the company a worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is the majority shareholder of Myovant.
4.8 / 5.0 (137)

Myovant Sciences Ltd. reports have an aggregate usefulness score of 4.8 based on 137 reviews.

Myovant Sciences Ltd.

Most Recent Annual Report

Myovant Sciences Ltd.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Myovant Sciences Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!